To our knowledge, there are currently no other studies of single agent ipilimumab in RCC and the ongoing trials are evaluating the efficacy of combining ipilimumab with PD-1 blockade in RCC [40]. This evidence concerns the gene RPL17 and renal cell carcinoma.